此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

2026年10月12日 更新者:Novartis Pharmaceuticals

VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome, Followed by an Open-Label Extension Period

The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.

研究概览

详细说明

This is a randomized, double-blind, placebo-controlled study with a 52-week duration evaluating the efficacy and safety of arumakimig in participants with VEXAS who are receiving glucocorticoids. Participants will be randomized 1:1 to either arumakimig or placebo.

Following the double-blind period, participants may have the option to enter a 2-year (104-week) open-label extension (OLE) period, continuing until Week 156.

A 16-week safety follow-up period must be completed after the OLE (up to Week 172) or after the double-blind period (up to Week 68).

研究类型

介入性

注册 (估计的)

120

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Novartis Pharmaceuticals
  • 电话号码:+41613241111

学习地点

      • Fukushima、日本、9601295
        • 招聘中
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama、Kanagawa、日本、2360004
        • 招聘中
        • Novartis Investigative Site
    • Osaka
      • Suita、Osaka、日本、5650871
        • 招聘中
        • Novartis Investigative Site
    • Tokyo
      • Hachiōji、Tokyo、日本、1930998
        • 招聘中
        • Novartis Investigative Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male and female participants aged ≥18 years at screening.
  • Somatic mutation in UBA1 gene known to be associated with VEXAS.
  • Participants must have at least two manifestations of VEXAS at screening or in the past 6 months.
  • Participants must be able to start treatment for Pneumocystis jiroveci pneumonia (PJP) during the study if indicated according to the local guidelines.
  • Ability to communicate well with the Investigator, understand and agree to comply with the requirements of the study.

Exclusion Criteria:

  • Participants meeting any of the following criteria are not eligible for this study:
  • Positive serology for hepatitis B surface antigen (HBsAg) excludes the participant.

HBsAg negative participants who are hepatitis B core antibody (HBcAb) positive are also excluded unless protocol-defined criteria are met.

  • Participants with a positive HCV antibody test should have HCV ribonucleic acid (RNA) levels measured. Participants with positive (detectable) HCV RNA must be excluded. Chronic hepatitis C patients who have completed HCV anti-viral treatment must be HCV-RNA negative at least 12 weeks after treatment before randomization to be eligible.
  • Active viral, bacterial, or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infections.
  • Known or suspected Human Immunodeficiency Virus (HIV) infection. Should it be required by local regulations and/or considered appropriate by the Investigator, an HIV test can be performed locally to confirm eligibility.
  • Live vaccinations within a certain period prior to arumakimig treatment. Live vaccines are prohibited during the trial and up to a certain period following the last dose of arumakimig.
  • History of malignancy of any organ system, including post-transplant lymphoproliferative disorder (except for skin Bowen's disease, completely treated and resolved, localized squamous or basal cell carcinoma of the skin or actinic keratosis that have been treated with no evidence of recurrence in the past 12 weeks, in situ cervical cancer or non-invasive malignant colon polyps that have been removed), treated or untreated, within a protocol-defined period, regardless of whether there is evidence of local recurrence or metastases.
  • History of or current hepatic disease (moderate to severe Hepatic Impairment as per Child-Pugh classification), including but not limited to, acute or chronic hepatitis (for Hepatitis B or C), cirrhosis or hepatic failure.
  • Participants of child-bearing potential who do not agree to comply with required contraceptive use as outlined in the protocol.

Other protocol-defined inclusion/exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Arumakimig

Arumakimig from Day 1 to Week 52 during the double-blind period. Eligible participants may then continue into an open-label extension and receive arumakimig through Week 156.

Arumakimig Injection

其他名称:
  • MAS825

Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement.

安慰剂比较:Placebo

Placebo from Day 1 to Week 52 during the double-blind period. Eligible participants may then continue into an open-label extension and receive arumakimig through Week 156.

Arumakimig Injection

其他名称:
  • MAS825

Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement.

Placebo Injection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of participants achieving improvement of key VEXAS manifestations and oral glucocorticoid (GC) reduction at Week 52
大体时间:From baseline up to Week 52

Response is defined as meeting both criteria:

A) Clinical domain: In participants with clinical disease activity in any domain at baseline, complete resolution of clinical manifestations related to active disease in at least one affected domain. In participants with no clinical disease activity in any domain at baseline, continued absence of clinical manifestations in all domains at Week 52.

AND B) Protocol-defined glucocorticoid reduction through 52 weeks.

From baseline up to Week 52

次要结果测量

结果测量
措施说明
大体时间
Number of participants achieving Overall Clinical Response (OCR) at Week 52
大体时间:From baseline up to Week 52

Achieving OCR at Week 52 is defined as meeting all the following criteria:

  • Absence of active inflammatory manifestations of VEXAS
  • Protocol-defined reduction in oral glucocorticoid.
  • Protocol-defined reduction in C reactive protein.
From baseline up to Week 52
Number of participants achieving resolution of VEXAS manifestations
大体时间:From baseline up to Week 52

In participants with clinical disease activity in any domain at baseline, achieving complete resolution of clinical manifestations.

From baseline up to Week 52
Number of participants with oral glucocorticoid reduction
大体时间:From baseline up to Week 52

Number of participants achieving protocol-defined glucocorticoid dose reduction through 52 weeks.

From baseline up to Week 52
Total number of flare-free days over 52 weeks
大体时间:Up to 52 weeks

Total cumulative number of days over 52 weeks meeting the protocol-defined criteria for a flare-free day.

Up to 52 weeks
Number of participants achieving Hematologic Improvement - Erythroid (HI-E) during the double-blind treatment period
大体时间:From baseline up to Week 52

Hematologic Improvement - Erythroid (HI-E) during the double-blind 52-week treatment period among participants with baseline hemoglobin within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria.

From baseline up to Week 52
Number of participants achieving Hematologic Improvement - Platelets (HI-P) during the double-blind treatment period
大体时间:From baseline up to Week 52

Hematologic Improvement - Platelets (HI-P) during the double-blind 52-week treatment period among participants with baseline platelets within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria.

From baseline up to Week 52
Number of participants without worsening disease according to a participant-reported questionnaire
大体时间:From baseline up to Week 52

Participants without protocol-defined worsening of disease according to a participant-reported questionnaire.

From baseline up to Week 52
Time to death during the double-blind treatment period
大体时间:Up to 52 weeks

Assessment of mortality through Week 52 in each treatment arm.

Up to 52 weeks
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
大体时间:Up to 172 weeks

Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms and laboratory values qualifying and reported as AEs.

Up to 172 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月30日

初级完成 (估计的)

2028年12月26日

研究完成 (估计的)

2031年4月15日

研究注册日期

首次提交

2026年7月31日

首先提交符合 QC 标准的

2026年7月31日

首次发布 (实际的)

2026年8月6日

研究记录更新

最后更新发布 (实际的)

2026年10月13日

上次提交的符合 QC 标准的更新

2026年10月12日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅